**Lay Description of Important Outcomes**

* Our research results were presented at 20th Anniversary R3 Symposium: Replication, Repair and Recombination, June 2-3, 2023; oral presentation; Ithaca, NY
* A manuscript is in preparation that describes the impact of two-drug combination on tumor growth metastasis in immune competent MBC cells.
* The data generated within this project helped to obtain the funding support from DoD CDMRP BCRP.
* Our basic science research helped to develop a clinical trial for patients with advanced gastrointestinal tract cancers, IRB protocol I-650120. TAS-102 (Lonsurf) is provided by Taiho and Talazoparib by Pfizer. This trial evaluates dose and biomarkers for TAS102-Talazoparib application.